Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II Cytokine Working Group trials

Journal of Clinical Oncology

Volumn 19, Issue 13, 2001, Pages 3194-3202

  Flaherty, L E ^a   Atkins, M ^a   Sosman, J ^a   Weiss, G ^a   Clark, J I ^a   Margolin, K ^a   Dutcher, J ^a   Gordon, M S ^a   Lotze, M ^a   Mier, J ^a   Sorokin, P ^a   Fisher, R I ^a   Appel, C ^a   Du, W ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035397975     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.13.3194     Document Type: Article

References (40)

1. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
2. Cutaneous melanoma
3. Chemotherapy of melanoma
4. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
5. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
6. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
7. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
8. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma
9. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study
10. Randomized, doubleblind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
11. Phase III trial of dacarbazine versus dacarbazine with interferon alfa-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study
12. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
13. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
14. Multi-institutional phase II trial of intensive combination chemotherapy for metastatic melanoma
15. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma
16. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
17. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience
18. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer
19. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2), and interferon alfa-2b (IFN) in patients with metastatic melanoma
20. Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM)
21. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 Patients
22. Efficacy of interleukin-2 in the treatment of metastatic melanoma: Systemic review and metaanalysis
23. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
24. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in meta-static malignant melanoma
25. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
26. Updated analysis of an outpatient chemoinnumotherapy regimen for treating metastatic melanoma
27. Chemoinnumotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
28. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma: A pilot study
29. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma
30. Cancer Biotherapy Research Group (CBRG) trial 94-11: Outpatient subcutaneous interleukin-2 [Proleukin] and interferon alfa-2b [Intron A] with combination chemotherapy plus tamoxifen in the treatment of metastatic melanoma
31. Sequential biochemotherapy of IFN-alfa/IL-2, cisplatin (CDDP), dacarbazine (DTIC) and carmustine (BCNU): Results of a monocenter phase II study in 109 patients with advanced metastatic malignant melanoma (MMM)
32. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma
33. False positive rates of randomized phase II designs
34. S100-beta melanomainhibiting activity and lactate dehydrogenase discriminate progressive from nonprogressive stage IV melanoma
35. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic melanoma
36. A new American Joint Committee on Cancer staging system for cutaneous melanoma
37. Prognostic factors for survival of patients treated systemically for disseminated melanoma
38. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
39. Dacarbazine, cisplatin, and interferon alfa with or without interleukin-2 in advanced melanoma: Interim analysis of EORTC trial 18951
40. Phase III randomized trial of cisplatin, vinblastine, and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-Alfa-2b (INF) versus CVD in patients (pts) with metastatic melanoma